In the UK, a breakthrough “living drug” has been given to an NHS patient with aggressive leukaemia, opening access to a powerful personalised therapy that can deliver long-term remission and potential cures.
Leukaemia, the most common cancer in children, is becoming less frequent worldwide. A major global study shows that between 1990 and 2021, childhood leukaemia rates steadily declined—bringing real progress in the fight against this disease.
